BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 30983008)

  • 1. A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
    Ng ZY; Bishton M; Ritchie D; Campbell R; Gilbertson M; Hill K; Ratnasingam S; Schwarer A; Manos K; Shorten S; Ng M; Nelson N; Xin L; De Mel Widanalage S; Sunny T; Purtill D; Poon M; Johnston A; Cochrane T; Lee HP; Hapgood G; Tam C; Opat S; Hawkes E; Seymour J; Cheah CY
    Hematol Oncol; 2019 Aug; 37(3):253-260. PubMed ID: 30983008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
    Tseng YD; Stevenson PA; Cassaday RD; Cowan A; Till BG; Shadman M; Graf SA; Ermoian R; Smith SD; Holmberg LA; Press OW; Gopal AK
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):282-287. PubMed ID: 29061536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
    Sakellari I; Mallouri D; Batsis I; Apostolou C; Konstantinou V; Abela EM; Douka V; Marvaki A; Karypidis K; Iskas M; Baliakas P; Kaloyannidis P; Yannaki E; Sotiropoulos D; Kouvatseas G; Smias C; Anagnostopoulos A
    Leuk Lymphoma; 2015; 56(11):3071-81. PubMed ID: 25760637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
    Xin X; Lin L; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Meng F; Cao Y; Zhu X; Zhang Y
    Cytotherapy; 2024 May; 26(5):456-465. PubMed ID: 38385909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
    Wu R; Ma L
    Cell Transplant; 2023; 32():9636897231179364. PubMed ID: 37350429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
    Flowers CR; Costa LJ; Pasquini MC; Le-Rademacher J; Lill M; Shore TB; Vaughan W; Craig M; Freytes CO; Shea TC; Horwitz ME; Fay JW; Mineishi S; Rondelli D; Mason J; Braunschweig I; Ai W; Yeh RF; Rodriguez TE; Flinn I; Comeau T; Yeager AM; Pulsipher MA; Bence-Bruckler I; Laneuville P; Bierman P; Chen AI; Kato K; Wang Y; Xu C; Smith AJ; Waller EK
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1197-1205. PubMed ID: 27040394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.
    Singer S; Dean R; Zhao Q; Sharma N; Abounader D; Elder P; Hofmeister CC; Benson DM; Rosko A; Penza S; Andritsos L; Vasu S; Jaglowski S; William BM; Bolwell B; Pohlman B; Kalaycio M; Jagadeesh D; Hill B; Sobecks R; Devine SM; Majhail NS; Efebera YA
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1107-1115. PubMed ID: 30716453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
    Cohen YI; Lebel E; Zimran E; Shaulov A; Stepensky P; Grisariu S; Avni B
    Transplant Cell Ther; 2023 Aug; 29(8):505.e1-505.e8. PubMed ID: 37160229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
    Ogura M; Yamamoto K; Morishima Y; Wakabayashi M; Tobinai K; Ando K; Uike N; Kurosawa M; Gomyo H; Taniwaki M; Nosaka K; Tsukamoto N; Shimoyama T; Fukuhara N; Yakushijin Y; Ohnishi K; Miyazaki K; Sawada K; Takayama N; Hanamura I; Nagai H; Kobayashi H; Usuki K; Kobayashi N; Ohyashiki K; Utsumi T; Kumagai K; Maruyama D; Ohmachi K; Matsuno Y; Nakamura S; Hotta T; Tsukasaki K;
    Cancer Sci; 2018 Sep; 109(9):2830-2840. PubMed ID: 29957865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
    Jagadeesh D; Majhail NS; He Y; Ahn KW; Litovich C; Ahmed S; Aljurf M; Bacher U; Badawy SM; Bejanyan N; Cairo M; Cerny J; Epperla N; Farhadfar N; Freytes CO; Gale RP; Haverkos B; Hossain N; Inwards D; Kamble RT; Kenkre VP; Lazarus HM; Lazaryan A; Lekakis L; Mei M; Murthy HS; Mussetti A; Nathan S; Nishihori T; Olsson RF; Ramakrishnan Geethakumari P; Savani BN; Yared JA; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M
    Cancer; 2020 May; 126(10):2279-2287. PubMed ID: 32049359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
    Costes-Tertrais D; Hueso T; Gastinne T; Thieblemont C; Oberic L; Bouabdallah K; Garciaz S; Tchernonog E; Dartigeas C; Ribrag V; Fogarty P; Casasnovas RO; Houot R; Delette C; Malak S; Fornecker LM; Gressin R; Damaj G; Le Gouill S
    Bone Marrow Transplant; 2022 Apr; 57(4):627-632. PubMed ID: 35149851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
    Seyfarth B; Kuse R; Sonnen R; Glass B; Schmitz N; Dreger P
    Ann Hematol; 2001 Jul; 80(7):398-405. PubMed ID: 11529465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
    Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
    [No Abstract]   [Full Text] [Related]  

  • 17. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO).
    García-Noblejas A; Cannata-Ortiz J; Conde E; González Barca E; Gutiérrez N; Rojas R; Vidal MJ; Ramírez MJ; Jiménez-Ubieto A; García-Ruiz JC; Sancho JM; López A; Ríos Rull P; Novelli S; Albo C; Debén G; López-Guillermo A; Nicolás C; González de Villambrosia S; Mercadal S; Martín García-Sancho A; Arranz R
    Ann Hematol; 2017 Aug; 96(8):1323-1330. PubMed ID: 28536895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma.
    Kuruvilla J; Nagy T; Pintilie M; Tsang R; Keating A; Crump M
    Cancer; 2006 Jan; 106(2):353-60. PubMed ID: 16329112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy and Safety of Beam and Team Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients.
    Deveci B; Ateşoğlu EB; Bayrak E; Kublashvili G; Toptaş T; Saba R; Gülbaş Z
    Transplant Proc; 2023; 55(1):235-241. PubMed ID: 36639277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
    Olivieri J; Mosna F; Pelosini M; Fama A; Rattotti S; Giannoccaro M; Carli G; Tisi MC; Ferrero S; Sgherza N; Mazzone AM; Marino D; Calimeri T; Loseto G; Saraceni F; Tomei G; Sica S; Perali G; Codeluppi K; Billio A; Olivieri A; Orciuolo E; Matera R; Stefani PM; Borghero C; Ghione P; Cascavilla N; Lanza F; Chiusolo P; Finotto S; Federici I; Gherlinzoni F; Centurioni R; Fanin R; Zaja F;
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1814-1822. PubMed ID: 29857196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.